Pharmaceuticals

Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO

SUZHOU, China, Sept. 20, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, metabolic and other major diseases, announced today that the data for tw...

2019-09-20 14:30 8914

2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%

SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced trial data from the esophageal squamous cell carcinoma (ESCC) cohort of a Phase Ib clinical trial of the Company's investigational anti-PD-L1 antibody CS1001 in an oral pre...

2019-09-19 23:48 2273

Advanced Aesthetic Technologies and China National Biotec Group Announce Strategic Cooperation

BROOKLINE, Massachusetts, Sept. 19, 2019 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. (AAT), a leader in aesthetic gel implant technology, and China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM) today announced the execution of ...

2019-09-19 23:12 3406

Tresiba® Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

BARCELONA, Spain, Sept. 19, 2019 /PRNewswire/ -- According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in a...

2019-09-19 18:01 2217

Innovent Provides Update on the Results of IBI305 for the First-line Treatment of Advanced Non-squamous Cell Lung Cancer by Oral Presentation at CSCO

SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, metabolic and other major diseases, announced today that the results of ...

2019-09-19 16:36 8510

Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection

PLYMOUTH MEETING, Pennsylvania, Sept. 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that the company and its collaborator The Wistar Institute have received a$4.6 million National Institutes of Health (NIH) grant in support of innovative research to tackle a...

2019-09-17 21:00 2967

AMPAC Fine Chemicals and SK biotek Become New US Corporation Focused on Expanded Support to the World's Pharmaceutical Industry

SACRAMENTO, California, Sept. 17, 2019 /PRNewswire/ -- SK Holdings, the holding company ofSouth Korea's SK Group, has established SK pharmteco, a U.S.-based Contract Manufacturing Organization (CMO) supporting Pharmaceutical Customers worldwide. This move combines SK biotek in Korea, SK biotek in...

2019-09-17 04:35 3011

Ping An Good Doctor Joins Forces with the People's Government of Guangxi Zhuang Autonomous Region to Build Internet Healthcare Platform Opening up a Window for ASEAN to Seek Healthcare Services

SHANGHAI, Sept. 16, 2019 /PRNewswire/ -- The world's leading online healthcare ecosystem platform, Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; stock code: 01833.HK) entered into a strategic cooperation agreement (the "Agreement") with China Council for the Promotion ...

2019-09-16 21:04 6199
1 ... 182183184185186

Week's Top Stories